When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Cholangiocarcinoma

Last reviewed: 23 Jun 2024
Last updated: 09 Feb 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • painless jaundice
  • weight loss
  • abdominal pain
Full details

Other diagnostic factors

  • pruritus
  • triad of fever, jaundice, and RUQ pain
  • palpable gallbladder
  • hepatomegaly
  • dark urine
  • pale stools
  • asymptomatic
Full details

Risk factors

  • age >50 years
  • cholangitis
  • choledocholithiasis
  • cholecystolithiasis
  • other structural disorders of the biliary tract
  • ulcerative colitis (UC)
  • primary sclerosing cholangitis (PSC)
  • non-specific cirrhosis
  • alcoholic liver disease
  • liver fluke infection
  • chronic typhoid carrier
  • hepatitis C virus (HCV)
  • HIV
  • hepatitis B virus (HBV)
  • exposure to thorium dioxide
  • diabetes
  • cigarette smoking
  • exposure to toxins/medicines
  • male sex
Full details

Diagnostic tests

1st tests to order

  • serum bilirubin
  • serum alkaline phosphatase
  • serum gamma-GT
  • serum aminotransferase
  • serum prothrombin time
  • serum CA 19-9
  • serum carcinoembryonic antigen (CEA)
  • serum CA-125
  • abdominal ultrasound
  • abdominal CT
  • abdominal MRI
Full details

Tests to consider

  • endoscopic ultrasound (EUS)
  • MR angiography
  • ERCP
  • MRCP
  • percutaneous transhepatic catheterisation (PTC)
  • positron emission tomography (PET)
  • Immunostaining
Full details

Emerging tests

  • optical coherence tomography (OCT)
  • peroral cholangioscopy
  • duodenoscope-assisted cholangioscopy

Treatment algorithm

ACUTE

resectable disease

unresectable disease

Contributors

Authors

N. Joseph Espat, MD, MS, FACS

Chairman of Surgery

Professor

Director Cancer Center

Department of Surgery

Roger Williams Medical Center

Boston University School of Medicine

Providence

RI

Disclosures

NJE declares he has no competing interests.

Ponnandai Somasundar, MD, MPH, FACS

Associate Professor and Chief of Surgical Oncology

Department of Surgery

Roger Williams Medical Center

Boston University School of Medicine

Providence

RI

Disclosures

PS declares that he has no competing interests.

Acknowledgements

We would like to acknowledge our Gastroenterology expert panel member, Dr Brooks Cash, for his contribution to this topic.

Disclosures

BC declares that he has no competing interests.

Peer reviewers

Kevin Watkins, MD

Assistant Professor

Department of Surgery

Health Science Center

SUNY

Stony Brook

NY

Disclosures

KW declares that he has no competing interests.

Savio Reddymasu, MD

GI Fellow

Department of Medicine

Center for Gastrointestinal Motility

Division of Gastroenterology and Hepatology

University of Kansas Medical Center

Kansas City

KS

Disclosures

SR declares that he has no competing interests.

Satvinder Mudan, MBBS, BSc, MD, FRCS

Consultant in Surgical Oncology

The Royal Marsden Hospital

London

UK

Disclosures

SM declares that he has no competing interests.

  • Cholangiocarcinoma images
  • Differentials

    • Hepatocellular carcinoma (HCC)
    • Ampullary carcinoma
    • Pancreatic carcinoma
    More Differentials
  • Guidelines

    • NCCN clinical practice guidelines in oncology: hepatobiliary cancers
    • NCCN clinical practice guidelines in oncology: biliary tract cancers
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer